Beyond conventional care: The therapeutic potential of hemoperfusion in severe COVID-19

HP was well-tolerated in patients with severe COVID-19, and most studies reported improved clinical parameters, including better survival rates, when HP was used in patients with severe COVID-19. Further research, especially prospective studies, is needed to evaluate the utility of HP as an early and supportive therapy for critically ill patients due to infectious diseases, such as those with COVID-19 or severe sepsis.